AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10385137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both alpha-tocopherol and beta-carotene
Number of subjects: 15538
Study 10385137 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15538
Study 8889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 0
Study 8889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 0
Study 8889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 0
Study 8889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 0
Study 8889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 8889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment identification by investigators
Number of subjects: 0
Study 8889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment identification by coordinators
Number of subjects: 0
Study 8889344 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment identification
Number of subjects: 0
Study 1889771 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodilution therapy with hydroxyethyl-starch (HAES-steril) combined with pentoxifylline (Trental) for 6 months
Number of subjects: 42
Study 1889771 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 42
Study 6417717 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 36
Study 6417717 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 36
Study 3963860 — intervention group
Group type: EXPERIMENTAL
Intervention: MY-1 treatment (3 times a week from the 4th postoperative day for 3 weeks)
Number of subjects: 90
Study 3963860 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 90
Study 29198295 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright white light
Number of subjects: 44
Study 29198295 — intervention group
Group type: COMPARATOR
Intervention: Dim red light
Number of subjects: 44
Study 27324515 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% Chamaemelum nobile gel (0.5 mL/3 times a day)
Number of subjects: 60
Study 27324515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24338736 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (3 mg/day for 8 weeks)
Number of subjects: 300
Study 23470897 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 28
Study 23470897 — intervention group
Group type: COMPARATOR
Intervention: Contact/Measurement Control
Number of subjects: 28
Study 19657792 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal hormone therapy (50 microg estradiol plus 170 microg norethisterone/day)
Number of subjects: 50
Study 19657792 — intervention group
Group type: COMPARATOR
Intervention: No medication (Control)
Number of subjects: 50
Study 18441460 — intervention group
Group type: EXPERIMENTAL
Intervention: 11C‐acetate PET
Number of subjects: 78
Study 18441460 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 78
Study 16332385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiagabine (4 mg, two oral doses)
Number of subjects: 7
Study 16332385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 12556688 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy (5 x 10(6) IU twice daily for 5 days: every 4 weeks for three cycles, then every 8 weeks for seven cycles)
Number of subjects: 68
Study 12556688 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 68
Study 12556688 — intervention group
Group type: COMPARATOR
Intervention: Control (lamivudine/stavudine/indinavir)
Number of subjects: 68
Study 10641582 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 g oral glucose
Number of subjects: 20
Study 10641582 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 g oral glucose
Number of subjects: 20
Study 10641582 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 g oral glucose
Number of subjects: 20
Study 10641582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 8545223 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose surfactant therapy (beractant, 150 mg (6 mL)/kg, up to four doses, instilled every 6 hours for 20 minutes)
Number of subjects: 40
Study 8545223 — intervention group
Group type: COMPARATOR
Intervention: Air placebo (6 mL/kg)
Number of subjects: 40
Study 8545223 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose surfactant therapy
Number of subjects: 40
Study 1869100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus cyclophosphamide
Number of subjects: 32
Study 1869100 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, cyclophosphamide, and doxorubicin
Number of subjects: 32
Study 1869100 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 32
Study 1869100 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 32
Study 1869100 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evidence of disease
Number of subjects: 32
Study 6347788 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 240 mg/day
Number of subjects: 12
Study 6347788 — intervention group
Group type: EXPERIMENTAL
Intervention: verapamil 360 mg/day
Number of subjects: 12
Study 6347788 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 30633135 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone
Number of subjects: 2831
Study 30633135 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2831
Study 29336385 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone (4 mg) with/without droperidol (0.625 mg)
Number of subjects: 502
Study 29336385 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 502
Study 29336385 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone with/without droperidol (in patients with ≥2 risk factors)
Number of subjects: 502
Study 29336385 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group with ≥2 risk factors)
Number of subjects: 502
Study 27592122 — intervention group
Group type: EXPERIMENTAL
Intervention: ezParent program
Number of subjects: 312
Study 25375367 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting injectable paliperidone palmitate
Number of subjects: 0
Study 25375367 — intervention group
Group type: COMPARATOR
Intervention: Oral antipsychotic medications
Number of subjects: 0
Study 22335830 — intervention group
Group type: EXPERIMENTAL
Intervention: Medial and lateral entry pinning
Number of subjects: 160
Study 22335830 — intervention group
Group type: COMPARATOR
Intervention: Lateral entry pinning
Number of subjects: 160
Study 20646185 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU) 1,000mg every 12 weeks
Number of subjects: 50
Study 20646185 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB) gel (3-6 g/daily)
Number of subjects: 50
Study 20646185 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU)
Number of subjects: 50
Study 17546307 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid, cytological screening, and testing for human papillomavirus
Number of subjects: 100800
Study 17546307 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100800
Study 15705734 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric contractions (Iso)
Number of subjects: 0
Study 15705734 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions (Con)
Number of subjects: 0
Study 15705734 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions (Ecc)
Number of subjects: 0
Study 15705734 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric contractions (Con) relative to maximal Iso torque
Number of subjects: 0
Study 15705734 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric contractions (Ecc) relative to maximal Iso torque
Number of subjects: 0
Study 15705734 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluntary activation
Number of subjects: 0
Study 15705734 — intervention group
Group type: EXPERIMENTAL
Intervention: Coactivation
Number of subjects: 0
Study 15705734 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical responses to single and paired stimuli
Number of subjects: 0
Study 12010906 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA (Percutaneous Transluminal Coronary Angioplasty)
Number of subjects: 3608
Study 12010906 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCA
Number of subjects: 3608
Study 12010906 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG (Coronary Artery Bypass Grafting)
Number of subjects: 3608
Study 12010906 — intervention group
Group type: EXPERIMENTAL
Intervention: All causes
Number of subjects: 3608
Study 12010906 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac causes
Number of subjects: 3608
Study 12010906 — intervention group
Group type: EXPERIMENTAL
Intervention: Angina at 5 years
Number of subjects: 3608
Study 10582755 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic variceal ligation
Number of subjects: 185
Study 10582755 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic variceal sclerotherapy
Number of subjects: 185
Study 10582755 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 185
Study 8826572 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproic acid (divalproex sodium), starting dosage 250 mg bid, titrating to 1000 mg/d if necessary
Number of subjects: 0
Study 1676225 — intervention group
Group type: EXPERIMENTAL
Intervention: 20G disposable needles
Number of subjects: 92
Study 1676225 — intervention group
Group type: EXPERIMENTAL
Intervention: 26G disposable needles
Number of subjects: 92
Study 6373302 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg sublingual isosorbide dinitrate (ISDN)
Number of subjects: 30
Study 6373302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30993651 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 0
Study 30993651 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 0
Study 29343232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg∙kg‐1 (Group D2)
Number of subjects: 75
Study 29343232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg∙kg‐1 (Group D1)
Number of subjects: 75
Study 29343232 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (Group D0)
Number of subjects: 75
Study 29343232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg∙kg‐1
Number of subjects: 75
Study 29343232 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 2 μg∙kg‐1
Number of subjects: 75
Study 26547514 — intervention group
Group type: EXPERIMENTAL
Intervention: ACB + ABS
Number of subjects: 15
Study 26547514 — intervention group
Group type: COMPARATOR
Intervention: ACB alone
Number of subjects: 15
Study 24823873 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide treatment group (n=30)
Number of subjects: 60
Study 24823873 — intervention group
Group type: COMPARATOR
Intervention: Intensive insulin therapy group (n=30)
Number of subjects: 60
Study 22418004 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior 90° partial fundoplication
Number of subjects: 461
Study 22418004 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior 180° partial fundoplication
Number of subjects: 461
Study 22418004 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication
Number of subjects: 461
Study 20403176 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO with cooling at 34 degrees C for 48 to 72 hours
Number of subjects: 0
Study 20403176 — intervention group
Group type: COMPARATOR
Intervention: ECMO at 37 degrees C (control group)
Number of subjects: 0
Study 18525081 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio computer-assisted self-interviewing
Number of subjects: 818
Study 18525081 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face interview
Number of subjects: 818
Study 18525081 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerized interview
Number of subjects: 818
Study 15798702 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 84
Study 15798702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril with bisoprolol
Number of subjects: 84
Study 15798702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril with carvedilol
Number of subjects: 84
Study 15798702 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of enalapril with irbesartan
Number of subjects: 84
Study 12065984 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior long fusion (surgical treatment)
Number of subjects: 17
Study 12065984 — intervention group
Group type: COMPARATOR
Intervention: Nonoperated group (conservative treatment)
Number of subjects: 17
Study 10452757 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 800 microg daily for 6 months
Number of subjects: 30
Study 10452757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 8535033 — intervention group
Group type: EXPERIMENTAL
Intervention: goralatide (12.5 or 62.5 micrograms/kg/day, d1‐d4)
Number of subjects: 84
Study 8535033 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 84
Study 2136866 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention combined with drug treatment during hospitalization
Number of subjects: 0
Study 2136866 — intervention group
Group type: COMPARATOR
Intervention: Control group (unipolar patients and families)
Number of subjects: 0
Study 2136866 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention
Number of subjects: 0
Study 729629 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 50 mg administered orally
Number of subjects: 12
Study 729629 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide 50 mg administered intravenously
Number of subjects: 12
Study 729629 — intervention group
Group type: COMPARATOR
Intervention: Furosemide treatment
Number of subjects: 12
Study 29669064 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-only warning
Number of subjects: 1011
Study 29669064 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic health warning + text
Number of subjects: 1011
Study 29669064 — intervention group
Group type: COMPARATOR
Intervention: No claim (control) condition
Number of subjects: 1011
Study 29669064 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no warning)
Number of subjects: 1011
Study 28187051 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of PEEP (12 cmH2O)
Number of subjects: 242
Study 28187051 — intervention group
Group type: COMPARATOR
Intervention: Low levels of PEEP (≤2 cmH2O)
Number of subjects: 242
Study 26275354 — intervention group
Group type: EXPERIMENTAL
Intervention: 17-alpha hydroxyprogesterone caproate (17OHP-C)
Number of subjects: 443
Study 26275354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study 23706627 — intervention group
Group type: EXPERIMENTAL
Intervention: Minocycline 100mg orally, twice daily for 8 days
Number of subjects: 100
Study 23706627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21808963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MKH (midazolam 0.5 mg/kg and ketamine 6 mg/kg)
Number of subjects: 87
Study 21808963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MKL (midazolam 0.25 mg/kg and ketamine 3 mg/kg)
Number of subjects: 87
Study 21808963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M (midazolam 0.5 mg/kg)
Number of subjects: 87
Study 21808963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MKL
Number of subjects: 87
Study 21808963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M
Number of subjects: 87
Study 21808963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group MKH
Number of subjects: 87
Study 21808963 — intervention group
Group type: COMPARATOR
Intervention: Group MKL and Group MKH
Number of subjects: 87
Study 21808963 — intervention group
Group type: EXPERIMENTAL
Intervention: Group M, Group MKL, Group MKH
Number of subjects: 87
Study 19456855 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 50 mg
Number of subjects: 132
Study 19456855 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg
Number of subjects: 132
Study 19456855 — intervention group
Group type: COMPARATOR
Intervention: Both doses of amitriptyline
Number of subjects: 132
Study 16770567 — intervention group
Group type: EXPERIMENTAL
Intervention: IM warm-up (IMW) with 40% maximum inspiratory mouth pressure
Number of subjects: 10
Study 16770567 — intervention group
Group type: COMPARATOR
Intervention: Placebo IM warm-up (IMW(P)) with 15% maximum inspiratory mouth pressure
Number of subjects: 10
Study 16770567 — intervention group
Group type: COMPARATOR
Intervention: Control trial without IM warm-up
Number of subjects: 10
Study 15326251 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose betaINF-1a (60 microg IM/week)
Number of subjects: 30
Study 15326251 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11241549 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg bicalutamide (Casodex)
Number of subjects: 21
Study 11241549 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 9250639 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA (0.15 g/kg, maximum 5.0 g)
Number of subjects: 32
Study 9250639 — intervention group
Group type: COMPARATOR
Intervention: TAC (0.1 mL/kg, maximum 3.0 mL)
Number of subjects: 32
Study 9250639 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA
Number of subjects: 32
Study 9250639 — intervention group
Group type: COMPARATOR
Intervention: TAC
Number of subjects: 32
Study 9250639 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA and TAC
Number of subjects: 32
Study 7924888 — intervention group
Group type: EXPERIMENTAL
Intervention: Power spectral analysis (PSA) of heart rate variations
Number of subjects: 0
Study 7924888 — intervention group
Group type: EXPERIMENTAL
Intervention: Vibratory perception threshold (VPT) measured with a Suzuki‐Matsuoka Vibrometer (SMV‐5)
Number of subjects: 0
Study 2900918 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ethyl loflazepate (CM 6912)
Number of subjects: 12
Study 2900918 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ethyl loflazepate (CM 6912)
Number of subjects: 12
Study 2900918 — intervention group
Group type: COMPARATOR
Intervention: Inert placebo
Number of subjects: 12
Study 31945496 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC)
Number of subjects: 0
Study 31945496 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiol antioxidants (NAC/GSH)
Number of subjects: 0
Study 31945496 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) with malabaricone C (mal C)
Number of subjects: 0
Study 30949691 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component behavioral intervention with a Registered Dietitian Nutritionist, including a minimum of 6 one-on-one counseling sessions over ∼30 weeks focusing on healthy diet and physical activity goals.
Number of subjects: 47
Study 30949691 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC), n=24.
Number of subjects: 47
Study 30949691 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component behavioral intervention with a Registered Dietitian Nutritionist.
Number of subjects: 47
Study 28282363 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline Mental Component Summary (MCS) scores
Number of subjects: 520
Study 28282363 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline MCS scores
Number of subjects: 520
Study 28282363 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline pain visual analog scale
Number of subjects: 520
Study 27467702 — intervention group
Group type: EXPERIMENTAL
Intervention: Detached mindfulness
Number of subjects: 8
Study 27467702 — intervention group
Group type: COMPARATOR
Intervention: Brief exposure to alcohol-related thoughts
Number of subjects: 8
Study 23406728 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP02 120 mg/m²
Number of subjects: 44
Study 23406728 — intervention group
Group type: COMPARATOR
Intervention: irinotecan 300 mg/m²
Number of subjects: 44
Study 23406728 — intervention group
Group type: COMPARATOR
Intervention: docetaxel 75 mg/m²
Number of subjects: 44
Study 21215709 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic simulator (Teenaged video gamers)
Number of subjects: 30
Study 19925613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplementation (600 kcal/d)
Number of subjects: 253
Study 19925613 — intervention group
Group type: COMPARATOR
Intervention: Control supplement (200 kcal/d)
Number of subjects: 253
Study 16914336 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC 500/50 microg Diskus, 1 inhalation twice daily + placebo Handihaler, 1 inhalation once daily
Number of subjects: 90
Study 16914336 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 microg Handihaler, 1 inhalation once daily + placebo Diskus, 1 inhalation twice daily
Number of subjects: 90
Study 16914336 — intervention group
Group type: EXPERIMENTAL
Intervention: FSC 500/50 microg Diskus, 1 inhalation twice daily + tiotropium 18 microg Handihaler, 1 inhalation once daily
Number of subjects: 90
Study 14982910 — intervention group
Group type: EXPERIMENTAL
Intervention: Reteplase plus abciximab
Number of subjects: 253
Study 14982910 — intervention group
Group type: COMPARATOR
Intervention: Abciximab alone
Number of subjects: 253
Study 11358726 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg/day
Number of subjects: 32
Study 11358726 — intervention group
Group type: COMPARATOR
Intervention: Combined regimen (cetirizine, clarythromycin, topical corticosteroids, hydrating preparations)
Number of subjects: 32
Study 9145693 — intervention group
Group type: EXPERIMENTAL
Intervention: Ophthalmic fluorometholone-gentamicin
Number of subjects: 70
Study 9145693 — intervention group
Group type: COMPARATOR
Intervention: Ophthalmic betamethasone-gentamicin
Number of subjects: 70
Study 8174531 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopentone
Number of subjects: 75